In the July 2014 issue of Diabetes Care, written by Chiang, Kirkman, Laffel, and Peters, (Diabetes Care 2014; 37:2034–2054 | DOI: 10.2337/dc14-1140), new guidelines were provided for hemoglobin (hb) A1c. No longer are A1cs stratified by different age groups. Rather, new guidelines have been developed according to recent evidenced-based literature. They are as follows:

A new pill to treat adults with type 2 diabetes has been approved by the U.S. Food and Drug Administration.

Farxiga (dapaglifozin) tablets were approved to improve patients' blood sugar control, in combination with diet and exercise. The approval is based on findings from 16 clinical trials that included more than 9,400 people with type 2 diabetes.